News Release

Aralez Announces Several Corporate Updates
-The Company Reports Additional Steps Taken to Support the Submission of the YOSPRALA™ New Drug Application-
-The Company Announces the Promotional Launch of Fibricor® in the United States-

MILTON, Ontario, April 20, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced several corporate updates.

The Company reported additional details regarding the steps that have been taken to support the submission of the YOSPRALA (PA8140/PA32540) New Drug Application ("NDA") that was submitted to the Food and Drug Administration ("FDA") on March 14, 2016 using a new primary aspirin supplier for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. In an effort to strengthen the NDA submission with the new aspirin supplier, Aralez conducted human bioequivalence studies which compared the aspirin drug product manufactured from the original aspirin supplier to that from the new primary aspirin supplier. The bioequivalence studies tested both the 81 mg and 325 mg YOSPRALA doses. Study data demonstrated that the aspirin in YOSPRALA formulated from the original supplier was bioequivalent to that of the new primary supplier at both doses. The Company intends to publish these data in the near future. 

In addition, Aralez worked directly with the new primary aspirin supplier to help prepare it for a previously planned inspection by the FDA. The FDA inspection has recently concluded and did not result in any reported compliance findings. YOSPRALA's FDA Prescription Drug User Fee Act ("PDUFA") goal date for a decision is September 14, 2016.

The Company also announced the promotional launch of Fibricor® (fenofibric acid), comprised of both the branded product and the Authorized Generic ("AG"), in the United States with a 25 person sales force whose key objectives also include developing relationships with cardiologists. Fibricor operates in a large and heavily generalized market, which makes the AG an important option for medical professionals to prescribe, and the product has not been promoted since 2009.

"We believe the supportive bioequivalence studies together with the results of the recent FDA inspection of our new primary aspirin supplier are encouraging and help support the YOSPRALA NDA submission," said Adrian Adams, Chief Executive Officer of Aralez. "We are also excited that our first 25 sales representatives have officially started promotion of Fibricor and its Authorized Generic in the U.S. which have not been promoted since 2009 and operate in a large market. We anticipate that they will build strong relationships with key cardiologists which should lay a strong foundation for commercial excellence ahead of the potential approval of YOSPRALA."

As announced previously, James L. Hall will be appointed to General Manager of the Company's wholly owned subsidiary, Tribute Pharmaceuticals Canada Inc., effective May 16, 2016 and will be responsible for the overall operational, sales and marketing management of the Canadian operations.

About Aralez Pharmaceuticals Inc. 
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while focusing on creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in Ontario, Canada, the U.S. Headquarters is planned to be in Princeton, NJ and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at

The Company has developed an investigational aspirin therapy, known as YOSPRALA 81/40, containing 81 mg of aspirin, and YOSPRALA 325/40, containing 325 mg of aspirin. Both products are a coordinated-delivery tablet combining immediate-release omeprazole (40 mg), a proton pump inhibitor, layered around a pH-sensitive coating of an aspirin core developed with the goal of significantly reducing GI ulcers and other GI complications compared to taking enteric-coated or plain aspirin alone. This novel, patented product is intended for oral administration once a day and an indication is being sought for use for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers.

Cautionary Language Concerning Forward-Looking Statements  
This press release includes certain statements that constitute "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, the Company's ability to develop relationships with cardiologists ahead of the anticipated launch of YOSPRALA, pending FDA approval, the publishing data from the bioequivalence studies in the near future, YOSPRALA's September 14, 2016 PDUFA goal date, and other statements that are not historical facts, and such statements are typically identified by use of terms such as "may," "will," "would," "should," "could," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "likely," "potential," "continue" or the negative or similar words, variations of these words or other comparable words or phrases, although some forward-looking statements are expressed differently.  

You should be aware that the forward-looking statements included herein represent management's current judgment and expectations, and are based on current estimates and assumptions made by management in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that it believes are appropriate and reasonable under the circumstances, but there can be no assurance that such estimates and assumptions will prove to be correct and, as a result, the forward-looking statements based on those assumptions could prove to be incorrect. Accordingly, actual results, level of activity, performance or achievements or future events or developments could differ materially from those expressed or implied in the forward-looking statements. Readers are cautioned that actual future operating results and economic performance of the Company, including with respect to the forward-looking statements referred to above, are subject to a number of risks and uncertainties, including, among other things, those described below, and could differ materially from what is currently expected as set out in this press release.

Our operations involve risks and uncertainties, many of which are outside of our control, and any one or any combination of these risks and uncertainties could also affect whether the forward-looking statements ultimately prove to be correct and could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties include, without limitation, our inability to build, acquire or contract with a sales force of sufficient scale for the commercialization of YOSPRALA™ in a timely and cost-effective manner, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates (including YOSPRALA), including as a result of the need to conduct additional studies or due to issues with third-party API or finished product manufacturers, or the failure to obtain such approval of our product candidates for all expected indications, including as a result of changes in regulatory standards or the regulatory environment during the development period of any of its product candidates; the inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products, including our dependence on AstraZeneca and Horizon for the sales and marketing of VIMOVO, our dependence on Patheon for the manufacture of YOSPRALA™ 81/40 and YOSPRALA™ 325/40; our ability to protect our intellectual property and defend our patents; regulatory obligations and oversight; failure to make, integrate and maintain new acquisitions, such as the integration of Tribute; fluctuations in the value of certain foreign currencies, including the Canadian dollar, in relation to the U.S. dollar, and other world currencies; changes in government regulations, including tax laws and unanticipated tax liabilities; general adverse economic, market and business conditions; and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in the Company's SEC filings and reports and Canadian securities law filings, including in our Annual Report on Form 10-K for the year ended December 31, 2015 which are available on EDGAR at, on SEDAR at, and on the Company's website at, and those described from time to time in our future reports filed with the Securities and Exchange Commission and applicable securities regulatory authorities in Canada. You should not place undue importance on forward-looking statements and should not rely upon this information as of any other date. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

Contact Information:

Aralez Pharmaceuticals US Inc. 
Nichol Ochsner 
Executive Director,  
Investor Relations & Corporate Communications 


To view the original version on PR Newswire, visit:

SOURCE Aralez Pharmaceuticals Inc.